Who Paid My Doc
Gtx-102-Cl301
ClinicalTrials.gov NCT06617429
Research payments
$6,367,771
Through program year 2025, $6,367,771 in research payments was reported against Gtx-102-Cl301, across 133 payments, paid by Ultragenyx Pharmaceutical Inc..
- Paid by
- Ultragenyx Pharmaceutical Inc.
- ClinicalTrials.gov
- NCT06617429
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $6,367,771 | 133 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Elizabeth Berry-Kravis Chicago, IL Named on 17 payments
- Neha Bhatia Boston, MA Named on 11 payments
- Lynne Bird San Diego, CA Named on 11 payments
- Elizabeth Jalazo Chapel Hill, NC Named on 11 payments
- Paula Schleifer Miami, FL Named on 10 payments
- Jean-Baptiste Le Pichon Topeka, KS Named on 10 payments
- Bridget Ostrem Boston, MA Named on 9 payments
- Han Phan Atlanta, GA Named on 9 payments
- Andrea Lowden Irving, TX Named on 8 payments
- Cesar Ochoa-Lubinoff Los Angeles, CA Named on 7 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.